Causaly secures $60M to advance AI-driven drug discovery

London and San Francisco-based drug discovery AI startup, Causaly, has secured $60m in a series B funding round led by ICONIQ Growth. The funding will be used to expand the company’s presence in the US. Causaly utilises a combination of generative AI solutions and a best-in-class knowledge graph to enable biomedical researchers to rapidly synthesise and reference thousands of published research papers. The company claims its software can offer a 10x productivity gain for researchers, taking research that usually requires two-to-three years and completing it in two-to-three weeks. It hopes to use these methods to identify new treatments for diseases including Parkinson’s and multiple sclerosis.